AU2001281781A1 - Synthetic gagpol genes and their uses - Google Patents

Synthetic gagpol genes and their uses

Info

Publication number
AU2001281781A1
AU2001281781A1 AU2001281781A AU8178101A AU2001281781A1 AU 2001281781 A1 AU2001281781 A1 AU 2001281781A1 AU 2001281781 A AU2001281781 A AU 2001281781A AU 8178101 A AU8178101 A AU 8178101A AU 2001281781 A1 AU2001281781 A1 AU 2001281781A1
Authority
AU
Australia
Prior art keywords
gagpol genes
synthetic
genes
synthetic gagpol
generation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281781A
Inventor
Kurt Bieler
Ludwig Deml
Markus Graf
Ralf Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thermo Fisher Scientific Geneart GmbH
Original Assignee
Geneart AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001281781(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geneart AG filed Critical Geneart AG
Publication of AU2001281781A1 publication Critical patent/AU2001281781A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes. <IMAGE>
AU2001281781A 2000-05-18 2001-05-18 Synthetic gagpol genes and their uses Abandoned AU2001281781A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00110623A EP1156112B1 (en) 2000-05-18 2000-05-18 Synthetic gagpol genes and their uses
EP00110623 2000-05-18
PCT/EP2001/005744 WO2001088141A2 (en) 2000-05-18 2001-05-18 Synthetic gagpol genes and their uses

Publications (1)

Publication Number Publication Date
AU2001281781A1 true AU2001281781A1 (en) 2001-11-26

Family

ID=8168767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281781A Abandoned AU2001281781A1 (en) 2000-05-18 2001-05-18 Synthetic gagpol genes and their uses

Country Status (10)

Country Link
US (3) US7378515B2 (en)
EP (2) EP1156112B1 (en)
CN (1) CN1429270A (en)
AT (2) ATE318908T1 (en)
AU (1) AU2001281781A1 (en)
BR (1) BR0110706A (en)
CA (1) CA2408433A1 (en)
DE (2) DE60026199T2 (en)
HK (2) HK1042319B (en)
WO (1) WO2001088141A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9456201A (en) * 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
PL207168B1 (en) * 2001-09-20 2010-11-30 Glaxo Group Ltd Vaccines
DE10260805A1 (en) * 2002-12-23 2004-07-22 Geneart Gmbh Method and device for optimizing a nucleotide sequence for expression of a protein
ATE471335T1 (en) 2002-12-23 2010-07-15 Vical Inc VACCINES AGAINST INFECTIONS WITH THE HUMAN CYTOMEGALIVIRUS BASED ON CODONE-OPTIMIZED POLYNUCLEOTIDES
US20050220816A1 (en) * 2004-03-31 2005-10-06 Advanced Bioscience Laboratories, Inc. Mutant viral nucleic acids and vaccine containing same
DE502005008794D1 (en) 2004-08-03 2010-02-11 Geneart Ag PROCESS FOR MODULATING GENE EXPRESSION BY CHANGING THE CPG SIGNATURE
DE102004037611B4 (en) * 2004-08-03 2013-10-02 Geneart Ag Inducible gene expression
ES2281252B1 (en) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas RECOMBINANT VECTORS BASED ON THE MODIFIED ANKARA VIRUS (MVA) AS PREVENTIVE AND THERAPEUTIC VACCINES AGAINST AIDS.
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CN104245937B (en) 2012-04-17 2021-09-21 弗·哈夫曼-拉罗切有限公司 Methods of expressing polypeptides using modified nucleic acids
MX2021015193A (en) 2019-06-28 2022-01-18 Hoffmann La Roche Method for the production of an antibody.
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2274566T3 (en) * 1997-02-07 2007-05-16 MERCK &amp; CO., INC. SYNTHETIC GAG GENES OF HIV.
AU6139699A (en) 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
ATE333503T1 (en) 2006-08-15
DE60026199D1 (en) 2006-04-27
US8287881B2 (en) 2012-10-16
HK1042319B (en) 2006-10-20
US20040152069A1 (en) 2004-08-05
DE60026199T2 (en) 2006-11-23
WO2001088141A3 (en) 2002-04-18
US7378515B2 (en) 2008-05-27
HK1042319A1 (en) 2002-08-09
EP1282712A2 (en) 2003-02-12
WO2001088141A2 (en) 2001-11-22
US20130122585A1 (en) 2013-05-16
US20070293448A1 (en) 2007-12-20
DE60121572D1 (en) 2006-08-31
CA2408433A1 (en) 2001-11-22
DE60121572T2 (en) 2007-06-28
ATE318908T1 (en) 2006-03-15
CN1429270A (en) 2003-07-09
EP1156112A1 (en) 2001-11-21
EP1282712B1 (en) 2006-07-19
HK1053853A1 (en) 2003-11-07
BR0110706A (en) 2003-01-28
EP1156112B1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
AU2001281781A1 (en) Synthetic gagpol genes and their uses
GB2405406B (en) Viral vectors
AU2003275612A1 (en) Defructosylation method
AU4337196A (en) Bacillus-derived transglutaminase
AU681705B2 (en) Endosomolytically active particles
AU8719291A (en) Glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate synthases
IL151943A0 (en) HUMAN AMINOACYL-tRNA SYNTHETASE POLYPETIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS
AU5756298A (en) Attenuated salmonella strain used as a vehicle for oral immunization
CA2418442A1 (en) Novel helper functions for recombinant vector production
AU2002331332A1 (en) Sulfonium salts as phtoinitiators for radiation curable systems
EP1007720A4 (en) Dendritic cell hybrids
AU9338598A (en) Recombinant vector containing infectious, viral genome sequences greater than 100 kb, method for producing same and use for the mutagenesis of the viral sequences
EP1176205A3 (en) Expression of alkaline phosphatase in yeast
AU2001233132A1 (en) Hybrid adeno-retroviral vector for the transfection of cells
AU2002358691A1 (en) Vessel prosthesis, particularly for the replacement of aorta segments near the heart
AU5559499A (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO2002014526A3 (en) Replication competent aav helper functions
BR9803232A (en) Vaicna from neospora.
AU9730798A (en) Epoxide hydrolase
AU2003260816A1 (en) Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
WO2003106658A3 (en) Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
AU2001240078A1 (en) Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles
MXPA01003968A (en) Pestivirus mutants and vaccines containing the same.
AU2002224102A1 (en) Promoter for the culture of autrotrophic bacterium at high density
HUP0105230A2 (en) Use of specific hybrid promoters for controlling tissue expression